HARROWCatch this wave 3. I think we are almost finished wave 2 wich is mostly the most extreme. So now i expect the wave 3 is going to start.
−0.75USD
−24.41 MUSD
130.19 MUSD
30.06 M
About Harrow, Inc.
Sector
CEO
Mark L. Baum
Headquarters
Nashville
Website
Employees (FY)
315
Founded
2006
ISIN
US4158581094
FIGI
BBG000QXWY44
Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.
HROW: Can you guess what this pattern is called?See if you can guess it correctly. Earnings on 11/13
Eye Spy a MultibaggerI was hesitant to publish this chart because the extreme upside it shows will likely be viewed as unrealistic. However, HROW recently decisively broke above its 4-year trend channel as business developments have been quite positive lately - particularly with IHEEZO. This is a rare setup where the fu
HROW: Eye Spy A BottomHROW with a nice impulsive, 5-wave move off the low. HROW needs to hold the 0.618 retracement ($18.75) on this pull back, followed by a rally above the $19.95 local peak set today for further confirmation. Very bullish on the long-term prospects of this ticker.
HROW pull back - thoughts?Bounce off of 100 SMA, 2 long bullish candles with lots of volume, plus sound fundamentals. Any thoughts?
HROW - Long Setup Flag Setup with 2020 Insider Buying. Possible entry here or above 8.44., Stop signal 7.83, First target 9.23. 2nd Target Momentum.
Short Term Rise before head and shoulders completion?I see a short term rise in HROW as our current right shoulder of what looks to be a weekly head and shoulders hit a 61.8% Fibonacci retracement level with Stochastic RSI being as oversold as our last oversold areas. I drew two potential rises using some bear rally based Fibonacci Retracments, I feel
Harrow may bounce on lawsuit newsBack in May, a jury ruled in Harrow Health's favor in a lawsuit that Allergan filed against Harrow for intellectual property infringement. Allergan has been appealing the ruling, but today the two companies jointly filed an 8k form indicating that they had jointly dismissed all pending appeals and e
See all ideas
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of HROW is 12.35 USD — it has decreased by 2.37% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Harrow, Inc. stocks are traded under the ticker HROW.
Harrow, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
One year price forecast for Harrow, Inc. has a max estimate of 32.60 USD and a min estimate of 20.00 USD.
HROW earnings for the last quarter are −0.13 USD whereas the estimation was 0.04 USD which accounts for −454.54% surprise. Estimated earnings for the next quarter are −0.04 USD. See more details about Harrow, Inc. earnings.
Harrow, Inc. revenue for the last quarter amounts to 34.30 M USD despite the estimated figure of 37.58 M USD. In the next quarter revenue is expected to reach 37.86 M USD.
Yes, you can track Harrow, Inc. financials in yearly and quarterly reports right on TradingView.
Like other stocks, HROW shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Harrow, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 16, 2024, the company has 315.00 employees. See our rating of the largest employees — is Harrow, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Harrow, Inc. EBITDA is 12.96 M USD, and current EBITDA margin is 9.92%. See more stats in Harrow, Inc. financial statements.